Monopar Therapeutics Stock In The News

MNPR Stock  USD 34.26  1.45  4.06%   
Our overall analysis of Monopar Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Monopar Therapeutics. The specific impact of Monopar Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Monopar Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Monopar Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Monopar Therapeutics Backtesting and Monopar Therapeutics Hype Analysis.
To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Monopar Therapeutics Today Top News and Investor Outlook

Investing News at Macroaxis
Monopar therapeutics director Tsuchimoto sells $356k in stock
https://www.investing.com/news/insider-trading-news/monopar-therapeutics-director-tsuchimoto-sells-356k-in-stock-93CH-4138653
 Bullish
Investing News at Macroaxis
Monopar therapeutics director Starr sells $672k in stock
https://www.investing.com/news/insider-trading-news/monopar-therapeutics-director-starr-sells-672k-in-stock-93CH-4138652
 Bullish
Investing News at Macroaxis
Monopar therapeutics CEO Chandler Robinson sells $672k in stock
https://www.investing.com/news/insider-trading-news/monopar-therapeutics-ceo-chandler-robinson-sells-672k-in-stock-93CH-4138650
 Bullish
Yahoo News
Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
https://finance.yahoo.com/news/chardan-initiates-coverage-monopar-therapeutics-192436570.html
 Neutral
Investing News at Macroaxis
Chardan initiates Monopar stock with buy rating on Wilson disease drug
https://www.investing.com/news/analyst-ratings/chardan-initiates-monopar-stock-with-buy-rating-on-wilson-disease-drug-93CH-4105234
 Bullish
Macroaxis News: globenewswire.com
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
https://www.globenewswire.com/news-release/2025/06/11/3097422/0/en/Monopar-and-EDNOC-Announce-Expanded-Access-Program-for-MNPR-101-Zr-and-MNPR-101-Lu-in-Advanced-Cancers.html
 Neutral
seekingalpha News
Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%
https://seekingalpha.com/news/4454797-monopar-therapeutics-added-to-russell-3000-and-2000-indexes-stock-up-15?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Macroaxis News: globenewswire.com
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
https://www.globenewswire.com/news-release/2025/05/07/3075768/0/en/Monopar-Presents-ALXN1840-Late-Breaker-Data-at-EASL-2025.html
 Bullish
Yahoo News
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025
https://finance.yahoo.com/news/why-monopar-therapeutics-inc-mnpr-093707807.html
 Bullish
Macroaxis News: globenewswire.com
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
https://www.globenewswire.com/news-release/2025/04/29/3070092/0/en/Monopar-Announces-ALXN1840-Data-Selected-for-Late-Breaker-Presentation-at-EASL-Congress-2025.html
 Bullish

Monopar Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Monopar and other traded companies coverage with news coverage. We help investors stay connected with Monopar headlines for the 18th of August 2025 to make an informed investment decision based on correlating the impacts of news items on Monopar Stock performance. Please note that trading solely based on the Monopar Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Monopar Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Monopar Therapeutics investors visualize upcoming and past events in order to time the market based on Monopar Therapeutics noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Monopar Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Monopar Therapeutics' short interest history, or implied volatility extrapolated from Monopar Therapeutics options trading.

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.